Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in multiple investor and scientific conferences during September 2025. The company's leadership will participate in two major investor conferences: the Morgan Stanley Global Healthcare Conference on September 8 and the Baird Global Healthcare Conference on September 9, both featuring fireside chats with CEO Pravin U. Dugel.
Additionally, the company will have a significant presence at several scientific conferences in Paris, including EURETINA Innovation Spotlight, Ophthalmology Futures Forums, and the 25th EURETINA Congress. Key presentations will focus on the company's OTX-TKI treatment for diabetic retinopathy, featuring data from the HELIOS Clinical Trial. The scientific program will conclude with a presentation at The Retina Society's 58th Annual Scientific Meeting in Chicago.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la partecipazione a diversi convegni per investitori e scientifici nel corso di settembre 2025. La direzione prenderà parte a due importanti incontri per investitori: il Morgan Stanley Global Healthcare Conference l'8 settembre e il Baird Global Healthcare Conference il 9 settembre, entrambi con interventi in formato fireside chat del CEO Pravin U. Dugel.
Inoltre, la società sarà presente con rilievo a numerosi eventi scientifici a Parigi, tra cui EURETINA Innovation Spotlight, Ophthalmology Futures Forums e il 25th EURETINA Congress. Le presentazioni principali verteranno sul trattamento OTX-TKI per la retinopatia diabetica, includendo dati dallo studio clinico HELIOS. Il programma scientifico si concluderà con una presentazione al The Retina Society's 58th Annual Scientific Meeting a Chicago.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en varias conferencias para inversores y científicas durante septiembre de 2025. La dirección de la compañía asistirá a dos importantes conferencias de inversores: el Morgan Stanley Global Healthcare Conference el 8 de septiembre y el Baird Global Healthcare Conference el 9 de septiembre, ambas con charlas fireside a cargo del CEO Pravin U. Dugel.
Además, la empresa tendrá una destacada presencia en varios congresos científicos en París, incluidos EURETINA Innovation Spotlight, Ophthalmology Futures Forums y el 25th EURETINA Congress. Las presentaciones clave se centrarán en el tratamiento OTX-TKI para la retinopatía diabética, mostrando datos del ensayo clínico HELIOS. El programa científico finalizará con una presentación en el The Retina Society's 58th Annual Scientific Meeting en Chicago.
Ocular Therapeutix (NASDAQ: OCUL)는 2025년 9월 여러 투자자 및 학술 회의에 참가할 것이라고 발표했습니다. 회사 경영진은 두 차례의 주요 투자자 콘퍼런스에 참여합니다: 9월 8일 Morgan Stanley Global Healthcare Conference와 9월 9일 Baird Global Healthcare Conference에서 모두 Pravin U. Dugel CEO와의 파이어사이드 채팅을 진행합니다.
또한 회사는 파리에서 열리는 여러 학술 회의에 활발히 참여할 예정이며, 여기에는 EURETINA Innovation Spotlight, Ophthalmology Futures Forums, 그리고 25th EURETINA Congress가 포함됩니다. 주요 발표는 당뇨성 망막병증 치료제 OTX-TKI와 HELIOS 임상시험의 데이터를 중심으로 이루어집니다. 학술 프로그램은 시카고에서 열리는 The Retina Society's 58th Annual Scientific Meeting에서의 발표로 마무리됩니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé sa participation à plusieurs conférences investisseurs et scientifiques en septembre 2025. La direction prendra part à deux grandes conférences investisseurs : le Morgan Stanley Global Healthcare Conference le 8 septembre et le Baird Global Healthcare Conference le 9 septembre, toutes deux sous forme de discussions fireside avec le PDG Pravin U. Dugel.
Par ailleurs, la société sera fortement présente à plusieurs congrès scientifiques à Paris, notamment EURETINA Innovation Spotlight, Ophthalmology Futures Forums et le 25th EURETINA Congress. Les présentations principales porteront sur le traitement OTX-TKI pour la rétinopathie diabétique, incluant des données de l'essai clinique HELIOS. Le programme scientifique se conclura par une présentation au The Retina Society's 58th Annual Scientific Meeting à Chicago.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme an mehreren Investoren- und Wissenschaftskonferenzen im September 2025 bekannt gegeben. Die Unternehmensführung wird an zwei wichtigen Investorenveranstaltungen teilnehmen: dem Morgan Stanley Global Healthcare Conference am 8. September und dem Baird Global Healthcare Conference am 9. September, jeweils mit Fireside-Chats des CEO Pravin U. Dugel.
Zudem wird das Unternehmen auf mehreren wissenschaftlichen Konferenzen in Paris stark vertreten sein, darunter EURETINA Innovation Spotlight, Ophthalmology Futures Forums und der 25th EURETINA Congress. Die Hauptpräsentationen befassen sich mit der OTX-TKI-Behandlung der diabetischen Retinopathie und präsentieren Daten aus der HELIOS-Studie. Das wissenschaftliche Programm schließt mit einem Vortrag auf dem The Retina Society's 58th Annual Scientific Meeting in Chicago ab.
- None.
- None.
BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September 2025.
Upcoming Investor Conferences
Morgan Stanley 23rd Annual Global Healthcare Conference:
Fireside Chat Date/Time: Monday, September 8, 2025
Fireside Chat Time: 2:35 – 3:10 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY
Baird 2025 Global Healthcare Conference:
Fireside Chat Date/Time: Tuesday, September 9, 2025
Fireside Chat Time: 12:50 – 1:20 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY
A live webcast of the fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
Upcoming Scientific Conferences
EURETINA Innovation Spotlight (EIS): September 3, 2025
Paris, France
- Company Presentation: Ocular Therapeutix: Redefining the Retina Experience
Session: VEGF Related and Other Retinal Indications
Presentation Date/Time: Wednesday, September 3, 2025, 4:00 – 4:05 PM CET
Presenter: Peter K. Kaiser, MD, Chief Development Officer
Ophthalmology Futures Forums (OFF) Retina Forum 2025: September 3, 2025
Paris, France
- Panel Title: Is Diabetic Retinopathy the Overlooked Elephant in the Room?
Session: Panel 1
Panel Date/Time: Wednesday, September 3, 2025, 10:00 – 10:30 AM CET
Presenter: Arthur A. Ciociola, Global Head of Quality
- Panel Title: The Future of Tyrosine Kinase Inhibitors & Other Adjunctive Agents for AMD: Exits or Bust?
Session: Panel 4
Panel Date/Time: Wednesday, September 3, 2025, 11:50 – 12:20 PM CET
Presenter: Peter K. Kaiser, MD, Chief Development Officer
- Company Presentation: Ocular Therapeutix: Redefining the Retina Experience
Session: Company Presentations 1
Session Date/Time: Wednesday, September 3, 2025, 1:50 – 3:20 PM CET
Presenter: Peter K. Kaiser, MD, Chief Development Officer
25th EURETINA Congress: September 4-7, 2025
Paris, France
- Symposium Title: Advancing Retinal Disease Treatment: Exploring OTX-TKI’s Potential to Extend Treatment Durability
Session: Satellite Symposium
Session Date/Time: Saturday, September 6, 2025, 10:15 – 11:15 AM CET
Faculty: Patricio G. Schlottmann, MD; Anat Loewenstein, MD; Paolo Lanzetta, MD; Sobha Sivaprasad, MBBS
- ePoster Title: Macular Fluid Volumetric Outcomes Following a Single Axitinib Intravitreal Hydrogel (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy
Session Date/Time: ePoster available for viewing throughout duration of the Congress
Presenter: Margaret A. Chang, MD, MS
The Retina Society 58th Annual Scientific Meeting: September 10-13, 2025
Chicago, IL
- Presentation Title: Longitudinal quantitative ultra-widefield retinal leakage assessment and macular volumetric fluid outcomes following a single axitinib hydrogel (OTX-TKI) in the HELIOS trial for non-proliferative diabetic retinopathy
Session: Diabetes I
Presentation Date/Time: Thursday, September 11, 2025, 4:35 – 4:40 PM CET
Presenter: Justis P. Ehlers, MD
Exact medical conference presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Explore the Company’s new corporate branding and follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When and where will Ocular Therapeutix (OCUL) present at the Morgan Stanley Healthcare Conference 2025?
What clinical trial data will OCUL present at the EURETINA Congress 2025?
How can investors access Ocular Therapeutix's conference presentations?
What topics will Ocular Therapeutix discuss at the Ophthalmology Futures Forums 2025?
